Activin type II receptor signaling in cardiac aging and heart failure.
Document Type
Article
Publication Date
3-6-2019
Keywords
JGM
JAX Source
Sci Transl Med 2019 Mar 6; 11(482):eaau8680
Volume
11
Issue
482
ISSN
1946-6242
PMID
30842316
DOI
https://doi.org/10.1126/scitranslmed.aau8680
Abstract
Activin type II receptor (ActRII) ligands have been implicated in muscle wasting in aging and disease. However, the role of these ligands and ActRII signaling in the heart remains unclear. Here, we investigated this catabolic pathway in human aging and heart failure (HF) using circulating follistatin-like 3 (FSTL3) as a potential indicator of systemic ActRII activity. FSTL3 is a downstream regulator of ActRII signaling, whose expression is up-regulated by the major ActRII ligands, activin A, circulating growth differentiation factor-8 (GDF8), and GDF11. In humans, we found that circulating FSTL3 increased with aging, frailty, and HF severity, correlating with an increase in circulating activins. In mice, increasing circulating activin A increased cardiac ActRII signaling and FSTL3 expression, as well as impaired cardiac function. Conversely, ActRII blockade with either clinical-stage inhibitors or genetic ablation reduced cardiac ActRII signaling while restoring or preserving cardiac function in multiple models of HF induced by aging, sarcomere mutation, or pressure overload. Using unbiased RNA sequencing, we show that activin A, GDF8, and GDF11 all induce a similar pathologic profile associated with up-regulation of the proteasome pathway in mammalian cardiomyocytes. The E3 ubiquitin ligase, Smurf1, was identified as a key downstream effector of activin-mediated ActRII signaling, which increased proteasome-dependent degradation of sarcoplasmic reticulum Ca2+ ATPase (SERCA2a), a critical determinant of cardiomyocyte function. Together, our findings suggest that increased activin/ActRII signaling links aging and HF pathobiology and that targeted inhibition of this catabolic pathway holds promise as a therapeutic strategy for multiple forms of HF.
Recommended Citation
Roh J,
Hobson R,
Chaudhari V,
Quintero P,
Yeri A,
Benson M,
Xiao C,
Zlotoff D,
Bezzerides V,
Houstis N,
Platt C,
Damilano F,
Lindman B,
Elmariah S,
Biersmith M,
Lee S,
Seidman C,
Seidman J,
Gerszten R,
Lach-Trifilieff E,
Glass D,
Rosenzweig A.
Activin type II receptor signaling in cardiac aging and heart failure. Sci Transl Med 2019 Mar 6; 11(482):eaau8680